Detalles de la búsqueda
1.
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Circulation
; 141(10): 843-862, 2020 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31992065
2.
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.
Diabetes Obes Metab
; 23(2): 425-433, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33084149
3.
Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME.
Diabetes Obes Metab
; 23(5): 1173-1181, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33502090
4.
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial.
Diabetes Obes Metab
; 23(12): 2775-2784, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34463409
5.
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
Diabetes Obes Metab
; 23(8): 1886-1891, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33950573
6.
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
Eur Heart J
; 41(2): 209-217, 2020 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31504427
7.
Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension.
Circulation
; 139(18): 2098-2109, 2019 04 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-30786754
8.
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
Circulation
; 139(11): 1384-1395, 2019 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30586757
9.
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
Circulation
; 139(3): 351-361, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30586723
10.
Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.
Cardiovasc Diabetol
; 19(1): 176, 2020 10 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33050931
11.
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
Cardiovasc Diabetol
; 19(1): 200, 2020 11 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-33243221
12.
Kisspeptin and neurokinin B interactions in modulating gonadotropin secretion in women with polycystic ovary syndrome.
Hum Reprod
; 35(6): 1421-1431, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32510130
13.
Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial.
Diabetes Obes Metab
; 22(12): 2335-2347, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32744354
14.
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
Diabetes Obes Metab
; 22(4): 631-639, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31789445
15.
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
Diabetes Obes Metab
; 22(7): 1151-1156, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32115840
16.
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
Diabetes Obes Metab
; 22(7): 1141-1150, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32227432
17.
Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME.
Diabetes Obes Metab
; 22(7): 1207-1214, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32030863
18.
Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy.
Diabetes Obes Metab
; 22(3): 427-433, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31858718
19.
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Circulation
; 137(2): 119-129, 2018 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28904068
20.
Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
Diabetes Obes Metab
; 21(1): 136-145, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30091172